arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

ANAPTYSBIO, INC

ANAB
$50.81 ▼ -3.16 (-5.85%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
12 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
36
Health
Weak
Moderately Bearish
auto_awesome

Analytical Summary

ANAPTYSBIO, INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). On the positive side, Operating Margin (%) remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $1.5B
Dividend Yield —
Revenue Growth 157.0% ↘
Op. Margin 20.4% ↗
ROIC 130.3% ↗
FCF / Share $0.68 ↗
Trailing P/E —
Price / Book 38.3x
FCF Yield 1.3%
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

12-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$234.60M
↑ +157.0% —
Net Income Profit after all expenses
$-13.23M
↑ +90.9% —
Operating Margin Operating profit as % of sales
20.4%
↑ +116.2% 76th
FCF / Share Free cash flow per share
$0.68
↑ +114.3% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
51
Returns ↓
21
Financial Health
52
Cash Quality
8

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 12 years · 43 quarters